UBS raises DaVita stock price target to $287 on reimbursement outlook
UBS raised its price target for DaVita (DVA) to $287 from $270, citing improved phosphate binder operating income outlook and cost opportunities. The company expects a 1.5% to 2% Medicare update in 2027. DaVita's Q3 earnings beat estimates, with adjusted EPS of $3.82 and revenue of $3.58B, but shares fell due to cost concerns. The stock trades at a P/E of 15.88, considered undervalued by InvestingPro.
How this was made
The 30-second read
Why it matters
Analyst upgrade adds a modest catalyst, yet market reaction was muted, limiting trading urgency.
Market read
The article provides a minor update on DaVita's valuation without new earnings data, offering limited trading relevance.
What to watch
Potential regulatory changes to Medicare payments could affect long‑term profitability.
Background
UBS upgraded DaVita with a higher price target after the company reported Q3 earnings that beat estimates, but the earnings data had already been released earlier.
Ticker impact
UBS raised its price target on DaVita to $287 and noted Q3 earnings beat, but the earnings numbers were already public.
possible slight upside pressure as investors weigh the higher target against cost concerns
Analyst upgrade provides a new catalyst, yet earnings were previously reported and market reaction was muted.
Market effects
Limited; dialysis sector outlook unchanged.
U.S. healthcare equities may see slight attention.
Low; no broader macro impact.
Counterpoint
The target raise may be overly optimistic given cost pressures and uncertain reimbursement.
Key entities
- CompanyDaVita Inc.
U.S.-listed dialysis provider (NYSE:DVA).
- Financial InstitutionUBS
Equity research firm that raised the price target.
